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Administration of cyclophosphamide after transplantation (post-transplantation cyclophosphamide, PTC) has
shown promise in the clinic as a prophylactic agent against graft-versus-host disease (GVHD). An important
issue with regard to recipient immune function and reconstitution after PTC is the extent to which, in
addition to diminution of antihost allo-reactive donor T cells, the remainder of the nonhost allo-reactive
donor T cell pool may be affected. To investigate PTC’s effects on nonhost reactive donor CD8 T cells, ova-
speciﬁc (OT-I) and gp100-speciﬁc Pmel-1 T cells were labeled with proliferation dyes and transplanted into
syngeneic and allogeneic recipients. Notably, an intermediate dose (66 mg/kg) of PTC, which abrogated GVHD
after allogeneic HSCT, did not signiﬁcantly diminish these peptide-speciﬁc donor T cell populations. Analysis
of the rate of proliferation after transplantation illustrated that lymphopenic-driven, donor nonhost reactive
TCR Tg T cells in syngeneic recipients underwent slow division, resulting in signiﬁcant sparing of these donor
populations. In contrast, after exposure to speciﬁc antigens at the time of transplantation, these same T cells
were signiﬁcantly depleted by PTC, demonstrating the global susceptibility of rapidly dividing T cells after an
encounter with cognate antigen. In total, our results, employing both syngeneic and allogeneic minor
antigen-mismatched T cell replete models of transplantation, demonstrate a concentration of PTC that
abrogates GVHD can preserve most cells that are dividing because of the accompanying lymphopenia after
exposure. These ﬁndings have important implications with regard to immune function and reconstitution in
recipients after allogeneic hematopoietic stem cell transplantation.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic stem cell transplantation
(AHSCT) is a curative therapy for some blood cancers and has
the potential to be applied to many other malignancies,
although such use is hindered by the complication of graft-
versus-host disease (GVHD) [1-5]. Graft-versus-host
responses are immediately initiated after transplantation
by rapidly cycling donor T cells that are not tolerant to host
allogeneic transplantation antigens [6-10]. Efforts to remove
antihost alloantigen reactive T cells ex vivo before trans-
plantation are ongoing, but practical as well as technical
issues have thus far precluded development of an effective
strategy [7,11,12]. Additionally, the low frequency of T cells
reactive with noneHLA-encoded (ie, minor) transplantation
antigens provides added challenges for successful ex vivo
deletion strategies [13,14]. Alkylating compounds induce
breaks in DNA, which initiate the apoptosis of the affected
cells upon entry into the replication cycle or necrotic death,
dependent on the cell population and conditions present
[15,16]. Regardless, these agents principally target dividing
cells. Studies utilizing alkylating agents in attempts to impart
immune tolerance were initiated in the late 1950s in
preclinical models [17-19]. Early studies demonstrated that
cyclophosphamide, an alkylating agent, could diminishedgments on page 1437.
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[20]. Subsequent work found that after low-dose total body
irradiation (TBI) conditioning and allogeneic bone marrow
infusion, cyclophosphamide administration could prevent
host T cells, which were responding to donor antigens, from
rejecting the graft and enabled donor hematopoietic
engraftment [21].
These ﬁndings, in part, rekindled interest in cyclophos-
phamide as a transient immunosuppressive strategy for
patients receiving AHSCT [22]. Recently, clinical trials have
been performed at several centers to begin assessing the
efﬁcacy of post-transplantation cyclophosphamide (PTC)
administration to ameliorate GVHD (http://clinicaltrials.gov/
show/NCT01427881) [23-25]. Results are thus far promising
for both safety and efﬁcacy of high-dose PTC administration,
as well as GVHD occurrence after both nonmyeloablative and
myeloablative conditioning in HLA-mismatched and HLA-
matched allogeneic HSCT recipients [26-28]. Depending on
the extent of conditioning and the status of the patient,
T cellereplete AHSCT is performed in the context of varying
degrees of lympho-depletion in the recipient. This post-
transplantation environment therefore supports both
lymphopenia-induced proliferation (LIP) antigen as well as
recipient allo-antigen antigen-stimulated proliferation, the
former driven by an excess of cytokines present that support
T cell homeostasis and maintenance in lympho-replete
immune compartments (eg, IL-7, IL-15) [29-32].
Because a major challenge after HSCT is reconstituting
immune function as quickly as possible [33-38], a critical
question after exposure to PTC concerns what populations ofTransplantation.
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Notably, pretransplantation conditioning was not employed
in the historical allo-tissue graft experiments, and in the
preclinical studies that examined engraftment, immune
function was not examined. Questions, therefore, remain
regarding the susceptibility of T cells undergoing LIP to
deletion after PTC administration. The goal of the current
study was to examine populations of T cells dividing because
of lymphopenia alone or together with antigen-driven acti-
vation in response to host allo-antigen or speciﬁc peptide
antigen in hematopoietic stem cell transplantation models
after exposure to PTC. The results demonstrated that PTC has
a markedly different impact on host reactive compared to
nonhost reactive transplanted donor T cellsdthe latter were
minimally affected by doses of PTC that ameliorated GVHD.
These ﬁndings are discussed in the context of potential
beneﬁts of PTC to facilitate immune responsiveness and
reconstitution after AHSCT.
MATERIALS AND METHODS
Mice
Seven to 8-week-old female C57BL/6 (B6), BALB/c, C3H.SW, and BALB.B
(C.B10-H2 b/LiMcdj) mice were purchased from Jackson Laboratories (Bar
Harbor, ME). Mice were maintained in pathogen-free conditions in the
Department of Microbiology and Immunology at the University of Miami
Miller School of Medicine. B6 mice congenic for CD45 and expressing the
CD45.1 allele (B6.SJL-Ptprc/BoAiTac), Pmel-1(B6.Cg-Thy1a/Cy Tg (TcraTcrb)
8Rest/J)/RAG-/-mice (Pmel-1 were a gift from Dr. Claudia Marcela Diaz), and
OT-I(C57BL/6- Tg (TcraTcrb)1100Mjb/J)/Rag/ mice were bred in facility.
Bone Marrow Transplantation
Donor C57BL/6 bone marrow, lymph nodes, and spleen were aseptically
removed. Single-cell suspensions of marrow, spleen, and lymph node cells
were washed in PBS. Donor bone marrow cells were treated with anti-Thy-
1.2 MACS magnetic beads (Miltenyi Biotec Inc., Auburn, CA) and negatively
selected to remove T cells and washed before transplantation. Spleen and
lymph node cells were incubated on anti-sIgecoated (Millipore (Billerica,
MA)) plastic dishes for 45 minutes at 4C to remove B cells. Nonadherent
cells were harvested and a small aliquot was stained with anti-CD4 and anti-
CD8 mAb to determine percentage contributions. Recipient C3H.SW mice
were irradiated with 10.5 Gy gamma-irradiation from an open beam Cobalt-
60 source (Gamma beam 150). Within 4 hours after irradiation, experi-
mental C3H.SW recipients were injected with C57BL/6 (45.1þ) allogeneic
bone marrow plus 2.3  106 sIg-depleted CD4þand CD8þ allogeneic T cells
(i.v. in .5 mL PBS). Transgenic donor CD8 T cell populations administered
were enriched using Miltenyi MACS magnetic bead separation and infused
at >90% purity. Recipient BALB.B mice were irradiated with 7.5 Gy gamma-
irradiation from an open beam Cobalt-60 source (Gamma beam 150).
Control T celledepleted bone marrow (TCD-BM) transplant recipients were
injected with allogeneic bone marrow (i.v. in .5 mL PBS). In recipients of
post-transplantation cyclophosphamide (Sigma St. Louis, MO), the indicated
concentrations were administered intraperitoneally on day 3 or days 3 and 4
and adjusted for weight of recipients.
Immunoﬂuorescence Staining and Analysis
The following ﬂuorescent antibodies were purchased from BD Biosci-
ences (San Jose, CA), eBioscience (San Diego, CA), BioLegend, and Invitrogen/
Life-TechnologieseMolecular Probes (Carlsbad, CA) and used for ﬂow cyto-
metric analysis: anti-va2 (B20.1), anti-vb5.1/5.2 (MR9-4), anti-CD90.1 (OX-
7), anti-CD62 L (MEL-14), anti-CD8a (53-6.7), anti-CD4 (RM4-5), anti-CD19
(6D5), anti-CD45.1(A20), anti-CD44 (IM7), and anti-IFN-g (XMG1.2). For
intracellular cytokine staining, single-cell suspensions prepared from
tissues were incubated (1  106/mL) in 10% complete medium with .1 nM
OVA257-284 (SIINFEKL) or .1 nM human gp10025-33, KVPRNQDWL (kindly
provided by Dr. Marcela Diaz-Montero, Department of Medicine, University
of Miami School of Medicine) and .7 mL BD GolgiStop protein transport
inhibitor containing monensin for 4 to 18 hours at 37C, surface stained,
ﬁxed and permeabilized with the FoxP3 staining kit (eBioscience) overnight,
stained intracellularly with the appropriate antibodies, washed, and
analyzed.
GVHD Assessment
Recipients were monitored for changes in total body weight and overall
survival. The clinical signs of GVHD were recorded for individual mice bymeans of a GVHD scoring system modiﬁed from Cooke et al. [39] Brieﬂy,
recipients were scored on a scale from 0 to 2 for 5 clinical parameters: (1)
weight loss (0,<10%; 1, 10% to 25%; 2, >25%); (2) diarrhea (0, not detectable;
1, mild; 2, severe); (3) fur texture (0, unremarkable; 1, slight back rufﬂing; 2,
entire body rufﬂing); (4) posture (0, normal; 1, hunching noted only at rest;
2, severe hunching and impaired movement); and (5) alopecia (0, unre-
markable; 1, mild to moderate; 2, severe with obvious areas of denuded
skin). The clinical score for a bone marrow transplantation (BMT) group
represents the average of at least 5 mice per group.
Antigen Stimulation
Whole splenocytes from C57BL/6-Tg(CAG-OVA)916Jen/J, which express
OVA in all tissues (kindly provided by Dr. Allison Bayer, Department of
Microbiology and Immunology, Diabetes Research Institute, University of
Miami School of Medicine), were infused i.p. and s.c. at 8 weeks after
transplantation. Recipients were bled 3 days later to assess for expansion of
OVA-speciﬁc T lymphocytes (OT-I) by Va2þVb5þCD8þ.
Cell Labeling and Proliferation
C3H.SW cells were labeled with PKH (Sigma) for donor cell identiﬁca-
tion when transplanted into syngeneic recipients Cell proliferation was
followed via the use of CFDA-SE, i.e. CFSE (Invitrogen) or Cell Trace (Invi-
trogen). Cells were labeled with between 5mM and 10mMproliferation dye
and incubated in PBS at 10 million cells per mL for 15 minutes at 37C. The
reaction was quenched using RPMI with 10% FBS (Gibco (Grand Island, NY))
and washed twice in PBS. Cells were immediately assessed on a Becton-
Dickson Fortessa Flow Cytometer (Franklin Lakes, NJ).
Statistical Analysis
All cell population persistence post-transplantation data are expressed
as the mean % or number  standard error of the mean (SEM). Weights and
percentage in later divisions are expressed as mean values. Statistical
comparisons were done using a nonparametric Mann-Whitney, 2-tailed P
value (95% conﬁdence interval) test using the GraphPad Prism program (La
Jolla, CA). Statistical signiﬁcance was deﬁned as a P value <.05.
RESULTS
Identiﬁcation of a PTC Dose That Ameliorated GVHD Did
Not Eliminate Slowly Dividing Donor T Cells
To identify an effective dose of PTC that would suppress
donor antihost allo-responses leading to GVHD, we
employed an allogeneic minor antigenemismatched hema-
topoietic stem cell transplantation model of GVHD involving
an MHC (H2b)-matched donor and recipient strain combi-
nation B6->C3H.SW [40,41]. Groups of C3H.SW recipients
exposed to 10.5 Gy TBI were injected with donor B6 TCD-BM
alone or together with 2.3  106 B6 T cells. Varying doses of
PTC (data not shown) were examined in C3H.SW recipients
over the course of several experiments (11 mg/kg to
66 mg/kg per dose delivered in 1 or 2 doses, which repre-
sents .275 mg to 3.3 mg total dose per 25 g mice), and single-
dose 200 mg/kg, which equaled 5.0 mgs per 25 g mice, and
was lethal in C3H.SW recipients (data not shown). In this
AHSCT model, a dose of 33 mg/kg but not 11 mg/kg admin-
istered on days 3 and 4 was found to signiﬁcantly ameliorate
GVHD-associated weight loss induced by infusion of 2.3 
106 sIg-depleted B6 splenocytes when C3H.SW recipients
were conditioned with lethal (10.5 Gy) TBI (Figure 1A).
Notably, improvement in survival (Figure S1) and GVHD
clinical score (data not shown) were also observed when
33 mg/kg  2 (66 mg total) was employed.
To more closely examine the effects of PTC on dividing
donor cell populations, sIg-depleted B6 splenocytes were
labeled with a carboxyﬂuorescein diacetate succinimidyl
ester (CFSE) cell proliferation dye and transplanted into
C3H.SW recipients. We then examined the effects of 2 doses
of PTC, 2  11 mg/kg and 2 x 33 mg/kg, on dividing donor
CD8þ T cells 5 days after transplantation. PTC administration
caused depletion of peaks representing later generations of
rapidly dividing cells in a dose-dependent fashion. Notably,
Figure 1. PTC after MHC-matched allogeneic HSCT ameliorates GVHD and reduces the percentage of donor T cells in later divisions 5 days after transplantation. (A)
GVHD-induced weight loss was reduced after 2  33 mg/kg PTC (B, n ¼ 6) and was not signiﬁcantly different from recipients of TCD-BM only (C, [P > .05; n ¼ 5]).
Recipients of 11 mg/kg PTC (:, n ¼ 5) exhibited slightly decreased weight loss versus the nonePTC-treated recipients (,, n ¼ 7) but did not differ signiﬁcantly
(P > .5). A representative experiment of 3 is shown. (B) To analyze how PTC impacts donor T cells early after HSCT, B6 sIg-depleted CD4 and CD8 T cells were labeled
with CFSE and transferred into lethal TBI (10.5 Gy)-conditioned C3H.SW recipients (n ¼ 5 per group). Varying doses (11 mg/kg or 33 mg/kg) of cyclophosphamide
(PTC) were administered i.p. at days 3 and 4 after transplantation. Data represents the percentage of donor T cells that had undergone at least 2 divisions at days 4 to 5
after transplantation. The CFSE dilution proﬁles indicated that there was greater reduction within the later generations of rapidly dividing donor CD8 T cells.
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(2  11 mg/kg), a population of cells remained evident that
divided greater than 5 times in the 5-day experimental
period. In contrast, at the 2 33 mg/kg concentration, whichFigure 2. PTC signiﬁcantly reduces transplanted donor T cell numbers after alloge
proliferation are susceptible to PTC in a dose-dependent manner. Note that the lo
C3H.SW sIg-CD4 and CD8 T cells were labeled with CFSE and PKH (when required) and
Results presented as representative histograms from individual mice (B6, n ¼ 6; C3H
postsyngeneic (upper panel) or allogeneic (lower panel) transplantation. Three strai
Allogeneic transplantations were performed using B6/BALB.B. Recipients received 2
the composite from 7 and 5 independent syngeneic and allogeneic experiments, res
recipients after administration of PTC. In contrast, cell numbers were signiﬁcantly resuccessfully diminished GVHD, the proﬁle was distinctly
different in that: (1) there was a more apparent diminution
of cells in later (>2) generations, and (2) only 2 to 3 gener-
ations of early dividing cells remained (Figure 1B). In total,neic but not syngeneic HSCT. (A) Cells responding to lymphopenia-induced
ss is most apparent in the more rapidly dividing generations. B6-CD45.1 or
injected into lethally conditioned (10.5 Gy) congenic and syngeneic recipients.
.SW, n ¼ 4) (B) Total cell numbers present in spleens of recipients 5 to 7 days
ns were utilized for the syngeneic transplantations: B6, C3H.SW, and BALB.B.
doses of 33 mg/kg PTC on days 3 and 4 after transplantation. Results represent
pectively. No signiﬁcant decrease in cell numbers was observed in syngeneic
duced in allogeneic recipients after treatment with the same PTC dose.
Figure 3. Survival and function of donor T cells undergoing division in the lymphopenic environment after syngeneic HSCT and 33 mg/kg x 2 PTC treatment. (A) 1 
106 OT-I Rag-/- or Pmel-1 Rag-/- CD8 T cells were labeled with CFSE and coinjected with 2.3  106 sIg-polyclonal B6 T cells into lethally irradiated syngeneic recipients.
PTC (33 mg/kg) was administered on days 3 and 4, and mice were sacriﬁced at day 5. Representative ﬂow analyses indicated there was virtually no reduction of CD8
Pmel-1 (n ¼ 2) and a small reduction of OT-I (n ¼ 6) cells. (B) Top: Pooled results of 3 independent experiments (n ¼ 6 mice) illustrating a small decrease of OT-I T cells
in the second or later division PTC (P ¼ .047). Bottom: Results from 2 pooled independent experiments using CFSE-labeled B6 polyclonal CD8 T cells. After trans-
plantation into B6 recipients, no signiﬁcant differences were observed in animals who did not or did receive PTC (33 mg/kg, day 3,4) administration. (C) OT-I donor
T cells surviving PTC are functionally responsive to antigen 2 months after HSCT. B6 recipients underwent transplantation with B6 T cells, OT-I, and TCD-BM as in 3A
and administered PTC (33 mg/kg) on days 3 and 4. After 60 days, mice were immunized with 20  106 splenocytes from B6-OVA tg mice. Three days later, the
percentage of Va2þ Vb5þ OT-I cells in the blood had signiﬁcantly increased in both nonePTC-treated and PTC-treated ova immunized recipients (P ¼ .02 and P ¼ .01,
respectively). (D) Donor OT-I T cells express effector cytokines when cultured in the presence of cognate antigen after PTC exposure. Animals were sacriﬁced and
splenocytes obtained 4 weeks after ovalbumin immunization with B6-OVA tg cells. Unfractionated cells (1  106/well) were incubated for 6 hours in the presence of
Brefeldin A and no antigen: 1 nM SIINFEKL (ova peptide: 257-264 chicken OVA, Kb binding) or 1 nM KVPRNQDWL (human gp100 peptide: 25-33 of human melanin
gp100, Db binding). Cells were then permeabilized and stained with anti-IFNg mAb. Values represent percent IFNg positive staining cells gated on the
Va2þCD8þpopulation.
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in a dose-dependent fashion; however, some slowly dividing
(1 to 2 divisions) cells were not deleted even after the
2  33 mg/kg protocol. The loss of rapidly dividing cells after
this PTC exposure was observed in many experiments using
several distinct strain combinations (data not shown).
Donor Cells Dividing Because of Lymphopenia Are
Essentially Spared after Exposure to PTC
Previous experiments by ourselves (D.R., R.B.L., unpub-
lished observations) and others have shown that cells
dividing because of lymphopenia divide approximately once
per 24 hours [42-44]. To elucidate whether 2 times the
injection of 33 mg/kg PTC spared the cells that were dividing
solely because of lymphopenia, CFSE-labeled T cells wereinfused into lethally conditioned syngeneic recipients. At
a concentration of PTC that ameliorated GVHD after AHSCT in
the allogeneic transplantation (2  33 mg/kg), the effect of
PTC in both B6 and C3H.SW recipients of syngeneic sIg-
depleted spleen cells was minimal to cells that had divided
more than once, with more than 50% of cells remaining after
treatment. A more vigorous depletion of cells was observed
at a higher concentration of PTC (ie, 2 66 mg/kg); however,
(1) T cells that had not undergone division were again
present, and (2) some T cells that had undergone only 1 or 2
divisions were again observed (Figure 2A).
The numbers of donor cells present after PTC was then
determined in syngeneic and allogeneic transplant recipients
(Figure 2B). No signiﬁcant diminution in total cell numbers
was observed in syngeneic recipients examined 5 to 7 days
Figure 4. PTC reduces numbers of nonhost reactive T cells in the presence but not absence of cognate antigen. (A) OT-I cell numbers recovered after recipient
treatment with PTC are not signiﬁcantly different in the absence of cognate antigen. B6 OT-I (1 or 5 x 106) T cells (Va2þ, CD90.2þ CD45.2þ) were injected with 2.3 
106 polyclonal B6 T cells (CD90.1þ) and 6  106 TCD-BM (CD90.1þ) into lethally irradiated (10.5 Gy) syngeneic recipients (CD45.1þ). PTC (2  33 mg/kg) was
administered at days 3 and 4. OT-I T cells were identiﬁed in the spleens of PTC recipients 5 days (left panel) or 8 weeks (right panel) after transplantation. (B) PTC
administration depletes antigen-speciﬁc CD8 OT-I T cells when cognate antigen is present. OT-I (1  106) cells were transferred into lethally irradiated syngeneic
recipients (10.5 Gy). Antigen stimulation was initiated on day 0 by infusion of 20  106 splenocytes from B6-OVA tg (1  107 s.c. and 1 107 i.p.). PTC (2  33 mg/kg)
was administered on days 3 and 4 after transplantation. Spleens were harvested 3 days later, and Va2þ Vb5þ CD8þ OT-I T cells were stained and assessed by ﬂow
cytometric analysis. Data represents OT-I cell numbers per spleen determined from the percentage CD8 T cells expressing Va2 and Vb5 and multiplying this
percentage by the calculated number of total CD8 T cells based on the numbers of viable (trypan blue negative) spleen cells (data not shown). Each data point
represents an individual mouse (n ¼ 4, n ¼ 6 per group).
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days 3 and 4 (Figure 2B, top). In contrast, a signiﬁcant loss of
cell number was observed in the spleens of B6->BALB.B
allogeneic transplantation experiments after the identical
day 3 and 4 PTC regimen after transplantation (Figure 2B,
bottom). These ﬁndings were consistent with the CFSE
dilution patterns observed after syngeneic and allogeneic
transplantation.
Based on the observations that donor CD8þ T cells
dividing as a consequence of lymphopenia were diminished
to a small degree, by PTC administered at a concentration
(33 mg/kg  2) that diminished GVHD (Figure 1), antigen-
speciﬁc T cells were subsequently included in the trans-
plantation inoculum to enable more precise monitoring of
the impact of the PTC regimen on nonantigen-driven donor T
cell proliferation after transplantation. Puriﬁed CD8þ pop-
ulations were obtained from B6-OT-I/Rag-/- and B6-Pmel-
1/Rag-/- TcR transgenic mice, labeled with cell proliferation
dye, and coadministered with B6 T cells to lethally ablated
syngeneic B6 recipients. We observed, as reported by others,
after sublethal irradiation [31], the rate of LIP by the CD8 OT-I
population (w1/day) was signiﬁcantly more rapid than that
by the Pmel-1 (w1 to 2 divisions through 1 week after
transplantation) CD8 T cells after transplantation into
syngeneic, lethally irradiated mice (Figure 3A). After
2  33 mg/kg PTC administration, minimal diminution of
CD8þ Pmel-1 T cells was observed and a small but consistent
decrease was detected in the OT-I population (Figure 3A).
This effect on the OT-I population was further evidenced in
several experiments in which examination of OT-I T cells
identiﬁed a decreasedalthough just at the margin of statis-
tical signiﬁcance (P¼ .047)din the percentage of these CD8 T
cells in the second or greater division after PTC wasadministered on days 3 and 4 after transplantation in
syngeneic recipients (85.6% versus 77.9% with and without
PTC, respectively, Figure 3B, upper). A similar pattern was
also observed after coinfused polyclonal B6 CD8þ Tcells were
transplanted and analyzed in syngeneic recipients (ie, no
statistically signiﬁcant decrease was observed whether or
not 2  33 mg/kg PTC was administered) (Figure 3B, lower).
We next asked whether cells that had been exposed to
PTC and persisted in transplant recipients maintained func-
tional responsiveness when stimulated by cognate antigen.
Syngeneic transplantations were, therefore, performed with
coadministered CD8þ OT-I T cells, B6 T cells (sIg-depleted
splenocytes), and 5  106 B6 (CD45.1) TCD-BM. Six to
8 weeks after transplantation, recipients who were
untreated or treated with PTC were exposed to ovalbumin
antigen after injection of splenocytes (2 107) from B6-OVA-
transgenic. The presence and expansion (see below) of the
transplanted donor OT-I (Va2þVb5þCD8þ T cells) were
evident in the blood of both untreated and PTC-treated
recipient groups (Figure 3C). Additionally, splenocytes ob-
tained after B6-ova (antigen) injection from these trans-
plantation groups of recipients were stimulated in vitro with
ova-peptide (SIINFEKL) for 6 hours and assessed for IFNg
production. Strong intracellular staining with anti-IFNgmAb
was observed in donor B6-CD8þVa2þ T cells stimulated
ex vivowith SIINFEKLdbut not an unrelated nonameric class
I H-2 Kb binding peptide (Figure 3D).
To more precisely quantify persistence and expansion of
OT-I T cells after 2 33 mg/kg PTC administration, syngeneic
B6 mice transplanted with 2.3  106 polyclonal T cells and
1  106 CD8-OT-I cells were sacriﬁced and numbers of
CD8þVa2þVbþ positive donor B6 T cells in the spleen were
calculated. Two months after transplantation, the number of
Figure 5. Persistence of non-antihost reactive donor T cells only in recipients treated with PTC and protected from GVHD. Recipient C3H.SW were conditioned with
a single dose of 10.5 Gy TBI on day 0. 2.1 106 CD4þ and CD8þ B6-CD45.1þ T cells with or without 2.1 106 B6 CD45.2þ OT-I CD8 T cells were coinfused together with
6  106 B6-CD45.1þ TCD-BM (n ¼ 4 mice per group). Some groups received 66 mg/kg i.p. injection of PTC on day 3. Recipient tissues were harvested on day 28 and
assessed for total cell numbers and numbers of OT-I T cells. (A) Total numbers of Va2þCD8þ CD45.1- (OT-I) T cells in lymph nodes of mice at day 29. P ¼ .003 and
P ¼ .03 for T cells only/T cells þ PTC and T cells þ OT-I/T cells þ OT-I þ PTC, respectively. (B) Total lymph node cell numbers at day 29 after transplantation. P ¼ .003 and
P ¼ .03 for T cells only/T cells þ PTC and T cells þ OT-I/T cells þ OT-I þ PTC, respectively (1 of 3 representative experiments). (C) Mean percentage weight loss versus
initial starting weight of each group of transplant recipients. T cells only versus T cells þ PTC: P ¼ .09; T cells þ OT-I versus T cells þ OT-I þ PTC: P ¼ .11.
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that received D.3 and 4 PTC administration compared with
the group that did not receive PTC (Figure 4A). To determine
the susceptibility of B6 CD8þOT-I T cells to this PTC regimen
under antigen-driven proliferation, these transgenic nonhost
reactive CD8 T cells together with B6 T cells were trans-
planted into syngeneic recipients and speciﬁc antigen
introduced (day 0) by injection of 2  107 splenocytes from
B6-ova Tg mice (Figure 4B). In contrast to ﬁndings obtained
in the absence of ovalbumin antigen (Figure 3), OT-I T cells
were signiﬁcantly depleted after days 3 and 4 (2 33mg/kg)
of PTC treatment (Figure 4B). These ﬁndings demonstrated
the effectiveness of the 2  33 mg/kg dose to deplete any
donor T cell population after efﬁcient antigen stimulation at
the time of transplantation before PTC exposure.Figure 6. Noneantihost reactive donor T cells are present >6 weeks after PTC treatme
conditioned with a single dose of 10.5 Gy TBI on day 0. 2.1  106 CD4þ and CD8þ B6-
were coinfused together with 6  106 B6-CD45.1 TCD-BM (n ¼ 4 mice per group). Som
splenic Va2þVb5þCD8þ CD45.1- CD90.1- (Ly9.1, which is expressed by C3H.SW T cells,
day 44 after transplantation. (B) Mean percentage weight loss versus initial starting w
P < .0001; T cells þ OT-I versus T cells þ OT-I þ PTC: P < .0001. (C) Mean clinical score
fur texture, and alopecia as described in Methods; of 3 representative experiments. T
I þ PTC: P ¼ .0005.In contrast to the 2 PTC dose injection regimen used in
clinical transplantations with a matched unrelated donor,
haplo-identical HSCT is currently performed using a single
injection of PTC [26]. To assess if a single PTC dose containing
the same total amount of cyclophosphamide resulted in
similar persistence of nonhost reactive donor CD8 T cells, B6-
CD45.2þ OT-I cells were coinfused with B6 CD45.1þ T cells
and bone marrow cells into lethally conditioned C3H.SW
CD45.2þ recipients, followed by injection of 66 mg/kg PTC at
day 3 after transplantation (Figure 5). Recipients of donor T
cells with or without coinfused B6 OT-I T cells who were
treated with PTC did not exhibit loss of cell numbers in
lymphoid tissue or weight loss reﬂective of GVHD in this
strain combination (Figure 5B,C). Notably, although few Va2þ
CD8þCD45.1 T cells were present in non-PTC treatednt in allogeneic HSCT recipients protected from GVHD. Recipient C3H.SW were
CD90.1þ T cells with or without 2.1  106 B6 CD45.2þCD90.2þ OT-I CD8 T cells
e groups received 66 mg/kg i.p. injection of PTC on day 3. (A) Total numbers of
was not detected on these cells; data not shown) OT-I T cells in spleens of mice
eight of each group of transplant recipients. T cells only versus T cells þ PTC:
of each transplantation group based on monitoring changes including posture,
cells only versus T cells þ PTC: P < .0001; T cells þ OT-I versus T cells þ OT-
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<10 gated events per mouse), these T cells were readily
detectable in lymph nodes in recipients treated on day 3with
66 mg/kg PTCw1 month after HSCT (Figure 5A). The ability
of PTC to facilitate persistence of noneantihost reactive OT-I
T cells while concomitantly inhibiting GVHD was corrobo-
rated in an independent transplantation, in which recipients
were examined >6 weeks after HSCT (Figure 6). PTC treat-
ment again clearly prevented weight loss and clinical signs
induced by GVHD (Figure 6B,C). Importantly, only in PTC-
treated animals were transplanted Va2þVb5þ CD8þ CD45.1-
CD90.1- OT-I cells present, indicating that these cells
survived the PTC treatment regimen, which ameliorated
GVHD (Figure 6A).
DISCUSSION
Bacterial, viral, and fungal infections are recurring
complications associated with the diminished immune
function after HSCT. Immune deﬁciency after transplantation
can arise as a consequence of conditioning, GVHD prophy-
laxis, and GVHD-associated suppression. The use of
methotrexate and cyclosporine to inhibit donor antihost
allo-reactive responses leading to GVHD after HSCT has been
the standard of care for more than 2 decades [45,46]. Strat-
egies that could block GVHD-inducing T cells while sparing
other populations to provide immunity against pathogens
and tumor antigens after transplantationwould represent an
advance in treatment. Recent clinical trials have provided
evidence that administration of cyclophosphamide after
T cellereplete allogeneic HSCTmay be a strategy tominimize
long-term immunosuppression [24]. In the present study, we
investigated the question of whether PTC results in a global
and equivalent diminution of all dividing T cells, or whether
antihost alloantigen-speciﬁc donor T cells may be more
effectively depleted than other populations. The ﬁndings
illustrate that, although nonhost allo-antigen reactive donor
T cells undergo some division early after transplantation in
the lymphopenic setting, cyclophosphamide can be admin-
istered at days 3 to 4 in a manner that predominantly spares
such cells while concomitantly depleting a sufﬁcient level of
antihost allo-reactive T cells to ameliorate GVHD.
In the 1970s, PTC administrationwas reported to promote
tolerance to allogeneic MHC-mismatched skin grafts in mice
[18]. These results were followed by the observation that
particular Vb TCR families were deleted after MHC-matched
allogeneic skin grafting and cyclophosphamide infusion was
performed, consistent with the hypothesis that the allo-
reactive T cell response was inhibited by PTC [47]. Notably,
these studies were not conducted under lymphopenic
conditions. Subsequent work by Luznik and Fuchs demon-
strated that PTC could promote engraftment after non-
myeloablative HSCT, supporting the notion that antihost
allo-antigen reactive donor T cells elicited after trans-
plantation could be eliminated [21]. Accordingly, the use of
PTC in clinical allogeneic stem cell transplantation was per-
formed based on the premise that this method of GVHD
prophylaxis would speciﬁcally deplete activated donor
antihost-speciﬁc Tcells, as initially proposed byNomoto et al.
after studies involving nonconditioned HSCT recipients [48].
However, whether or not PTC has a greater inﬂuence upon
reducing host allo-antigenespeciﬁc activity compared with
nonhost antigen reactive T cells undergoing LIP, which is
signaled by excess cytokine (eg, IL-7, IL-15) because of the
marked loss of cytokine receptor binding Tcells, has not been
examined. Although the abrogation of GVHD is a key goalafter AHSCT, the utility of PTC would be diminished if a more
global deletion of cells irrespective of their capacity to induce
GVHD simultaneously took place.
When CFSE-labeled B6 donor T cells were transplanted
into lethally conditioned allogeneic minor histo-
compatibilityemismatched C3H.SW recipients, a large
percentage of rapidly dividing cells were identiﬁed. After PTC
(66 mg/kg total dose) administration, most of these rapidly
dividing cells were eliminated and GVHD was signiﬁcantly
ameliorated. To assess how lymphopenic signals alone or
together with antigen signals inﬂuenced susceptibility of
transplanted T cells to PTC exposure, the addition of multiple
TcR transgenic CD8þ T cell populations were included
together with polyclonal donor CD8þ T cells. One population,
OT-I, possesses a TcR speciﬁcity generated by engineering
a RAG-/- B6 mouse to express a TcR Va and Vb segment that
yields a speciﬁcity for a peptide of hen egg white lysoszyme
(an antigen not normally found in the mouse) presented by
the MHC class I H2 Kb molecule. The second CD8 TcR trans-
genic population (ie, PMEL-1 with speciﬁcity for the gp100
melanoma antigen) is also presented by MHC Kb, and is an
antigen that is expressed in the skin and ocular tissue at low
levels. Notably, previous work by others reported more rapid
expansion kinetics under lymphopenic conditions of OT-I
CD8þ T cells (w1 division per 24 hours) versus PMEL-1
CD8þ T cells (w1 division per 34 hours) [42,44], and those
ﬁndings were corroborated in the present work. When
cotransplanted into lethally conditioned syngeneic recipi-
ents, neither CD8þ T cell transgenic population was signiﬁ-
cantly diminished by the PTC dose employed as assessed by
CFSE division and cell number (Figures 3,4). However, the
more rapid rate of LIP by OT-I than Pmel-1 T cells did appear
to consistently, although modestly, increase their suscepti-
bility to PTC. We interpret these ﬁndings to indicate that PTC
susceptibility was markedly higher for T cells dividing more
rapidly (multiple times per day) (ie, as a result of allo-anti-
genestimulated activation after transplantation). Consistent
with such a hypothesis was the ﬁnding that when OT-I CD8 T
cells were subsequently coinfused with splenocytes from
transgenic B6-OVAeproducing mice, the more rapid rate of
OT-I proliferation demonstrated by dye dilution was
accompanied by a large reduction in CD8 OT-I cell number
after PTC administration (Figure 4B). It is interesting that
freshly obtained OT-I T cells expressing a predominantly
naïve (ie, CD44-CD62Lþ) (Figure S2) phenotype become
highly susceptible to day 3 and 4 PTC administration after
antigen exposure because naïve donor T cells appear to
mediate severe GVHD responses, and, therefore, deletion of
responsive naïve T cells would presumably be important as
well as effective for GVHD prevention [10,49].
A key beneﬁt of post-transplantation usage of cyclo-
phosphamide in hematopoietic cell transplants is that the
pro-drug 4-hydroxycylcophosphamide is not converted to
the alkylating phosphoromide mustard compound in cells
expressing high levels of aldehyde dehydrogenase, which
includes hematopoietic stem cells, thus removing the
necessity for additional stem cell infusion [50-54]. Although
cyclophosphamide-induced alkylation can occur throughout
the cell cycle, it most effectively kills rapidly proliferating
cells, especially those in the G1 and S phases. Resistance can
result from several pathways, including increased drug
efﬂux, reaction of the drug with thiols (eg, glutathione), as
well as increased DNA repair time. Successful DNA repair
leading to survival requires the coordination of a number of
protein factors to the damaged area, access to the strands,
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unactivated and activated T cells convert cyclophosphamide
to the alkylating form, it is reasonable to propose that the
more rapid the expansion kinetics by a T cell population (eg,
one driven by allogeneic antigen to divide multiple times per
day) compared with the division stimulated by cytokines
under lymphopenic conditions (ie,wonce per18 to 36hours),
the less time there will be for the former to repair damage
caused in G1/S phase, resulting in death due to failure to
replicate damaged DNA [56,57]. Indeed, a consistent obser-
vation in our studies was the capacity of our PTC treatment
regimens to prevent induction of GVHD mediated by
donor T cells reactive with host allo-antigen epitopes
(Figures 1,5,6,S1). The ability to enhance DNA repair pathways
in selected cell populations could, therefore, provide
approaches to minimize and/or abrogate the loss of slowly
dividing cells with the objective to augment immediate
immune responsiveness and protection in recipients after
allogeneic hematopoietic stem cell transplantation.
The present study has important implications with regard
to immune function and/or reconstitution after T cell replete
allogeneic HSCT. Survival and responsiveness by those
infused T cells, which are not host allogeneic transplantation
antigen reactive, is crucial to provide patients with imme-
diate immune function and protection against both patho-
gens and residual hematopoietic tumor cells. The ﬁndings
here support the notion that the antigen and cytokine signals
present, which can rapidly induce T cell proliferation post-
HSCT, will have a major impact on determining the T cell
populations that persist after administration of day 3 and/or
4 post-transplantation cyclophosphamide, and accordingly,
the cells that can be exploited via vaccination or other means
to provide rapid adaptive immune function to protect indi-
viduals from opportunistic infections, as well as relapse after
transplantation. A critical issue to address concerns the fate
of anti-tumor reactive T cells in recipients treated with PTC.
We anticipate their survival will be inﬂuenced by the signals
noted above including the T cell receptor afﬁnity of the
clones involved which will inﬂuence the kinetics of division
and thereby the time available for DNA repair post-alkyl-
ation. We posit that together with the drug concentration
administered, development and application of strategies that
diminish nonhost allo-antigenespeciﬁc T cell proliferation
and promote DNA repair can better protect “desired” T cells
and, thereby, successfully facilitate more rapid and effective
immune function in such patients.ACKNOWLEDGMENTS
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